Close Navigation
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
OverlayOverlay
Artios logo

Find out more →

OverlayOverlay
Aura logo

Find out more →

INVESTING IN LIFE CHANGING SCIENCE

Discover more

Our Portfolio

With a focus on late pre-clinical to clinical stage ventures and covering a diversified range of therapeutic areas, we partner with the most ambitious scientists and entrepreneurs to build companies around game-changing life science innovation.

View full portfolio
Video
Video
Video

Team

Experienced and collaborative team, with deep industry and scientific expertise.

Meet the team
Mesh

Investors

Public market access to revolutionary medical innovation.

Find the latest share price, presentations, events and regulatory announcements here.

Visit Investor Centre
Share price

Latest News

Updates from Arix and our porfolio companies.

Read more news

Portfolio Company

4th October 2022

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

Portfolio Company

3rd October 2022

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Portfolio Company

28th September 2022

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Portfolio Company

27th September 2022

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022